Home > BIGG > Search result

    Results: 4

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Serogroup B Meningococcal (MenB) Vaccines in Adolescents and Young Adults (Including College Students)

    MMWR recomm. rep; 64 (41), 2015
    Two serogroup B meningococcal (MenB) vaccines have recently been licensed for use in the U.S. (MenB-FHbp [Trumenba, Wyeth Pharmaceuticals, Inc.] and MenB-4C [Bexsero, Novartis Vaccines]). Both vaccines were approved for use in persons aged 10 through 25 years. MenB-FHbp was licensed as a three-dose serie...
    Meningococcal Vaccines/therapeutic use, Meningococcal Infections/immunology, Neisseria meningitidis, Serogroup B/immunology
    Fulltext

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Yellow Fever Vaccine Booster Doses

    MMWR recomm. rep; 64 (23), 2015
    Yellow fever (YF) is a mosquito-borne viral disease that is endemic to sub-Saharan Africa and tropical South America. YF virus causes an estimated 200,000 cases of clinical disease and 30,000 deaths annually [WHO 1992]. Clinical disease ranges from a mild, undifferentiated febrile illness to severe disea...
    Yellow Fever Vaccine/therapeutic use, Yellow Fever/immunology, Yellow fever virus/drug effects
    Fulltext

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Serogroup B Meningococcal (MenB) Vaccines in Persons at Increased Risk for Serogroup B Meningococcal Disease

    MMWR recomm. rep; 64 (22), 2015
    In October 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal (MenB) vaccine (MenB-FHbp [Trumenba®, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., Philadelphia, Pennsylvania]) as a 3-dose series. The FDA licensed a second MenB vaccine (MenB-4C [Bexsero®...
    Meningococcal Vaccines/therapeutic use, Meningococcal Infections/immunology, Immunization Programs
    Fulltext

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of 9-Valent Human Papillomavirus Vaccine (9vHPV) in Females and Males

    MMWR recomm. rep; 64 (11), 2015
    GRADE was used to evaluate 9vHPV for routine vaccination of females and males aged 11 or 12 years as well as catch-up vaccination of females aged 13 through 26 years and males aged 13 through 21 years who were not vaccinated previously. Evidence of benefits, harms, values and preferences, and cost-effect...
    Papillomavirus Vaccines/therapeutic use, Human Papillomavirus Viruses/immunology, Papillomavirus Infections/complications
    Fulltext